Research Article

Impact of Interstitial Pneumonia on the Survival and Risk Factors Analysis of Patients with Hematological Malignancy

Table 6

Reviews of patients with HM and chemotherapy-related IP.

CaseAge/sexHematological diseasePresenting symptomsChemotherapyNumber of cyclesClinicopathological diagnosisOutcome

1M/42DLBCLCough, dyspneaR-CHOP2NSIPRecovery
2F/23ALLFeverInduction chemotherapy1NSIPRecovery
3M/55DLBCLCough, feverR-CHOP1NSIPDied
4M/62DLBCLFever, dyspneaCHOP1NSIPRecovery
5M/55DLBCLFeverR-CHOP2NSIPDied
6M/60AMLCoughInduction chemotherapy1NSIPDied
7M/17Hodgkin’s lymphomaFever, dyspneaABVD6BOOPRecovery

DLBCL: diffuse large B-cell lymphoma; ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; R-CHOP: rituximab, cyclophosphamide, epirubicin, vincristine, and prednisone; CHOP: cyclophosphamide, epirubicin, vincristine, and prednisone; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; NSIP: nonspecific interstitial pneumonia; BOOP: bronchiolitis obliterans organizing pneumonia.